| Dr James Blake Wiseman, PHARMD | |
|
34 Us Highway 68 E Unit A, Benton, KY 42025-8336 | |
| (270) 703-2529 | |
| Not Available |
| Full Name | Dr James Blake Wiseman |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 34 Us Highway 68 E Unit A, Benton, Kentucky |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477180727 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 016583 (Kentucky) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr James Blake Wiseman, PHARMD Po Box 766, Benton, KY 42025-0766 Ph: () - | Dr James Blake Wiseman, PHARMD 34 Us Highway 68 E Unit A, Benton, KY 42025-8336 Ph: (270) 703-2529 |
News Archive
While legislators in Moscow attempt to reform the Russian health system in a way that is "strikingly similar" to the reform process in the U.S. and "[g]iven the importance of the U.S.-Russia relationship ... our two countries have a historic opportunity to expand our health collaboration and, in so doing, improve our diplomatic ties," former U.S. Senate Majority Leader Bill Frist.
In a surprising discovery that someday may lead to new treatments for many inflammatory diseases, University of Utah scientists found that a hormone involved in iron metabolism can save mice from deadly acute inflammation.
ValenTx, Inc., announced today the closing of a $22 million Series B Preferred Stock financing. The round was led by SV Life Sciences and joined by Covidien Ventures, as well as all the Company's existing venture capital investors: Sapient Capital, EDF Ventures, Kaiser Permanente Ventures, Affinity Capital Partners, and TGap Ventures.
Research led by St. Jude Children-s Research Hospital investigators will likely impact how acute lymphoblastic leukemia is treated in young adults and shows older adolescent age does not dictate worse outcomes against the most common childhood cancer.
Alkermes, Inc. today announced the initiation of a phase 1/2 study of ALKS 5461 for treatment-resistant depression (TRD). ALKS 5461 is the combination of ALKS 33, a proprietary opioid modulator, and buprenorphine. TRD, which is also known as refractory depression, refers to depressive episodes that are not adequately controlled by standard antidepressant therapy.
› Verified 3 days ago
Mrs. Elisha Dougherty, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1004 Big Bear Hwy, Benton, KY 42025 Phone: 270-703-1169 | |
Dr. Amber Willett, PHARM.D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 817 Main St, Benton, KY 42025 Phone: 270-527-9374 Fax: 270-527-3152 | |
Rhonda Goins, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 310 W 5th St, Benton, KY 42025 Phone: 270-527-3597 | |
Mrs. Karen K Jones, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1112 Main St, Benton, KY 42025 Phone: 270-527-3616 Fax: 270-527-5520 | |
Staci Anderson, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 310 W 5th St, Benton, KY 42025 Phone: 270-527-3597 | |
Dr. Kayla Alexander, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 310 W 5th St, Benton, KY 42025 Phone: 270-527-3597 Fax: 270-527-0789 |